GlassScriptPhysician profile
Melhem A Dandan
NPI 1053393520
$1,761.85
in general payments reported to CMS, 2019-2025
26 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2021: $174 · 2022: $344 · 2023: $415 · 2024: $178 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.07 |
| Education | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.81 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $221.41 | 2019-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $204.73 | 2023-2025 | |
| Astellas Pharma US INC | $170.00 | 2023 | |
| Amgen INC. | $155.29 | 2024-2025 | Otezla, Otezla, Repatha |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2021 | |
| Lilly USA, LLC | $107.22 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Intuitive Surgical, INC. | $61.09 | 2019 | |
| Merck Sharp & Dohme LLC | $44.96 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Organon LLC | $44.30 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $38.51 | 2022-2025 | Solosec, Phexx, Phexxi |
| Mayne Pharma Commercial LLC | $33.48 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.28 | 2025 | Xifaxan |
| Therapeuticsmd, INC. | $31.39 | 2021 | |
| Applied Medical Resources Corporation | $27.63 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.65 | 2022 | |
| Biogen, INC. | $21.95 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $20.71 | 2023 | Cologuard Collection Kit |
| Meditrina | $19.85 | 2023 | |
| Exeltis, USA INC. | $18.30 | 2025 | Slynd |
| Lupin INC. | $17.35 | 2021 | |
| Axsome Therapeutics, INC. | $17.14 | 2023 | Auvelity |
| Becton, Dickinson and Company | $17.08 | 2022 | |
| Acessa Health INC. | $16.92 | 2019 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Hologic Sales and Service, LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melhem Dandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.